Emerging drugs in neuropathic pain

Bibliography

• Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms. In: Task force on taxonomy of the IASP, 2nd edn. Merskey H, Bogduk N (Eds) IASP Press, Seattle, WA, USA (1994):209-214.
   Google Scholar
• BACKONJA MM: Defining neuropathic pain. Anesth. Analg. (2003) 97:785-790.
   PubMed Web of Science ®Google Scholar
• DWORKIN RH, BACKONJA M, ROWBOTHAM MC et al.: Advances in neuropathic pain. Arch. Neurol. (2003) 60:1524-1534.
   PubMed Web of Science ®Google Scholar
• BOULTON AJ, ARMSTRONG WD, SCARPELLO JH, WARD JD: The natural history of painful diabetic neuropathy – a 4-year study. Postgrad. Med. J. (1983) 59:556-559.
   PubMed Web of Science ®Google Scholar
• MAX MB, SCHAFER SC, CULNANE M, DUBNER R, GRACELY RH: Association of pain relief with drug side effects in postherpetic neuralgia: a single-dose study of clonidine, codeine, ibuprofen, and placebo. Clin. Pharmacol. Ther. (1988) 43:363-371.
   PubMed Web of Science ®Google Scholar
• FIELDS HL, ROWBOTHAM M, BARON R: Postherpetic neuralgia: irritable nociceptors and deafferentation. Neurobiol. Dis. (1998) 5:209-227.
   Google Scholar
• JENSEN TS, GOTTRUP H, SINDRUP SH, BACH FW: The clinical picture of neuropathic pain. Eur. J. Pharmacol. (2001) 429:1-11.
   PubMed Web of Science ®Google Scholar
• HELIOVAARA M, IMPIVAARA O, SIEVERS K et al.: Lumbar disc syndrome in Finland. J. Epidemiol. Community Health (1987) 41:251-258.
   Web of Science ®Google Scholar
• SCHMADER KE: Epidemiology and impact on quality of life of postherpetic neuralgia and painful diabetic neuropathy. Clin. J. Pain (2002) 18:350-354.
   PubMed Web of Science ®Google Scholar
• DAVIS MP, WALSH D: Epidemiology of cancer pain and factors influencing poor pain control. Am J Hosp. Palliat. Care (2004) 21:137-142.
   Google Scholar
• VERMA S, ESTANISLAO L, SIMPSON D: HIV-associated neuropathic pain: epidemiology, pathophysiology and management. CNS Drugs (2005) 19:325-334.
   Google Scholar
• ARCHIBALD CP, SUTHERLAND J, GEDULD J, SUTHERLAND D, YAN P: Combining data sources to monitor the HIV epidemic in Canada. J Acquir Immune Defic Syndr (2003) 32(Suppl. 1):S24-S32.
   Google Scholar
• HU R, MUSTARD CA, BURNS C: Epidemiology of incident spinal fracture in a complete population. Spine (1996) 21:492-499.
   PubMed Web of Science ®Google Scholar
• WERHAGEN L, BUDH CN, HULTLING C, MOLANDER C: Neuropathic pain after traumatic spinal cord injury-relations to gender, spinal level, completeness, and age at the time of injury. Spinal Cord (2004) 42:665-673.
   PubMed Web of Science ®Google Scholar
• SANDRONI P, BENRUD-LARSON LM, MCCLELLAND RL, LOW PA: Complex regional pain syndrome type I: incidence and prevalence in Olmsted county, a population-based study. Pain (2003) 103:199-207.
   PubMed Web of Science ®Google Scholar
• TORRANCE N, SMITH BH, BENNETT MI, LEE AJ: The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J. Pain (2006) 7(4):281-289.
   Google Scholar
• ATLAS SJ, DEYO RA, PATRICK DL, CONVERY K, KELLER RB, SINGER DE: The Quebec Task Force classification for spinal disorders and the severity, treatment, and outcomes of sciatica and lumbar spinal stenosis. Spine (1996) 21:2885-2892.
   PubMed Web of Science ®Google Scholar
• COPLAN PM, SCHMADER K, NIKAS A et al.: Development of a measure of the burden of pain due to herpes zoster and postherpetic neuralgia for prevention trials: adaptation of the brief pain inventory. J. Pain (2004) 5:344-356.
   Google Scholar
• ZELMAN DC, DUKES E, BRANDENBURG N, BOSTROM A, GORE M: Identification of cut-points for mild, moderate and severe pain due to diabetic peripheral neuropathy. Pain (2005) 115:29-36.
   PubMed Web of Science ®Google Scholar
• BERGER A, DUKES EM, OSTER G: Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain (2004) 5:143-149.
   Google Scholar
• TURK DC: Clinical effectiveness and cost-effectiveness of treatments for patients with chronic pain. Clin. J. Pain (2002) 18:355-365.
   PubMed Web of Science ®Google Scholar
• GILRON I, WATSON CP, CAHILL CM, MOULIN DE: Neuropathic pain: a practical guide for the clinician. CMAJ (2006) 175(3):265-275.
   PubMed Web of Science ®Google Scholar
• DESHPANDE MA, HOLDEN RR, GILRON I: The impact of therapy on quality of life and mood in neuropathic pain: what is the effect of pain reduction? Anesth. Analg. (2006) 102(5):1473-1479.
   PubMed Web of Science ®Google Scholar
• FINNERUP NB, OTTO M, MCQUAY HJ, JENSEN TS, SINDRUP SH: Algorithm for neuropathic pain treatment: an evidence based proposal. Pain (2005) 118:289-305.
   PubMed Web of Science ®Google Scholar
• WANG LX, WANG ZJ: Animal and cellular models of chronic pain. Adv. Drug Deliv. Rev. (2003) 55(8):949-965.
   Google Scholar
• CAMPBELL JN, MEYER RA: Mechanisms of neuropathic pain. Neuron (2006) 52(1):77-92.
   PubMed Web of Science ®Google Scholar
• HANSSON PT, DICKENSON AH: Pharmacological treatment of peripheral neuropathic pain conditions based on shared commonalities despite multiple etiologies. Pain (2005) 113:251-254.
   PubMed Web of Science ®Google Scholar
• PARSONS CG: NMDA receptors as targets for drug action in neuropathic pain. Eur. J. Pharmacol. (2001) 429(1-3):71-78.
   PubMed Web of Science ®Google Scholar
• DICKENSON AH, MATTHEWS EA, SUZUKI R: Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur. J. Pain. (2002) 6(Suppl. A):51-60.
   Web of Science ®Google Scholar
• TSUDA M, INOUE K, SALTER MW: Neuropathic pain and spinal microglia: a big problem from molecules in ‘small’ glia. Trends Neurosci. (2005) 28(2):101-107.
   PubMed Web of Science ®Google Scholar
• FUNDYTUS ME: Glutamate receptors and nociception: implications for the drug treatment of pain. CNS Drugs (2001) 15:29-58.
   PubMed Web of Science ®Google Scholar
• CHIZH BA, HEADLEY PM: NMDA antagonists and neuropathic pain-multiple drug targets and multiple uses. Curr. Pharm. Des. (2005) 11:2977-2994.
   Web of Science ®Google Scholar
• CODERRE TJ, KUMAR N, LEFEBVRE CD, YU JSC: A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine and riluzole in a model of neuropathic pain. J. Neurochem. (2006) (In Press).
   Google Scholar
• ZHANG W, MURAKAWA Y, WOZNIAK KM, SLUSHER B, SIMA AA: The preventive and therapeutic effects of GCPII (NAALADase) inhibition on painful and sensory diabetic neuropathy. J. Neurol. Sci. (2006) 247:217-223.
   Google Scholar
• SUNG B, LIM G, MAO J: Altered expression and uptake activity of spinal glutamate transporters after nerve injury contribute to the pathogenesis of neuropathic pain in rats. J. Neurosci. (2003) 23:2899-2910.
   PubMed Web of Science ®Google Scholar
• BINNS BC, HUANG Y, GOETTL VM, HACKSHAW KV, STEPHENS RL Jr: Glutamate uptake is attenuated in spinal deep dorsal and ventral horn in the rat spinal nerve ligation model. Brain Res. (2005) 1041:38-47.
   PubMed Web of Science ®Google Scholar
• FISHER K, LEFEBVRE CD, CODERRE TJ: The effects of intrathecal administration of selective metabotropic glutamate receptor compounds in a rat model of neuropathic pain. Pharmacol. Biochem. Behav. (2002) 73:411-418.
   PubMed Web of Science ®Google Scholar
• BROWN DG, KRUPP JJ: N-methyl-d-aspartate receptor (NMDA) antagonists as potential pain therapeutics. Curr. Top. Med. Chem. (2006) 6:749-770.
   Web of Science ®Google Scholar
• GOGAS KR: Glutamate-based therapeutic approaches: NR2B receptor antagonists. Curr. Opin. Pharmacol. (2006) 6:68-74.
   Web of Science ®Google Scholar
• MATSUDA LA, LOLAIT SJ, BROWNSTEIN MJ, YOUNG AC, BONNER TI: Structure of a cannabinoid receptor and functional expression of the cloned CDNA. Nature (1990) 346:561-564.
   PubMed Web of Science ®Google Scholar
• MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
   PubMed Web of Science ®Google Scholar
• DEVANE WA, HANUS L, BREUER A et al.: Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 258:1946-1949.
   PubMed Web of Science ®Google Scholar
• MECHOULAM R, BEN-SHABAT S, HANUS L et al.: Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol. (1995) 50:83-90.
   PubMed Web of Science ®Google Scholar
• SUGIURA T, KONDO S, SUKAGAWA A et al.: 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun. (1995) 215:89-97.
   PubMed Web of Science ®Google Scholar
• AZAD SC, RAMMES G: Cannabinoids in anaesthesia and pain therapy. Curr. Opin. Anaesthesiol. (2005) 18:424-427.
   Web of Science ®Google Scholar
• PACHER P, BATKAI S, KUNOS G: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol. Rev. (2006) 58:389-462.
   PubMed Web of Science ®Google Scholar
• LEVER IJ, RICE AS: Cannabinoids and pain. Handbook Exp. Pharmacol. (2007) 177:265-306.
   Google Scholar
• SMART D, GUNTHORPE MJ, JERMAN JC et al.: The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br. J. Pharmacol. (2000) 129:227-230.
   PubMed Web of Science ®Google Scholar
• MAIONE S, BISOGNO T, DE NOVELLIS V et al.: Elevation of endocannabinoid levels in the ventrolateral periaqueductal grey through inhibition of fatty acid amide hydrolase affects descending nociceptive pathways via both cannabinoid receptor type 1 and transient receptor potential vanilloid type-1 receptors. J. Pharmacol. Exp. Ther. (2006) 316:969-982.
   PubMed Web of Science ®Google Scholar
• WATKINS LR, MAIER SF: Glia: a novel drug discovery target for clinical pain. Nat. Rev. Drug Discov. (2003) 2:973-985.
   Google Scholar
• MYERS RR, CAMPANA WM, SHUBAYEV VI: The role of neuroinflammation in neuropathic pain: mechanisms and therapeutic targets. Drug Discov. Today (2006) 11:8-20.
   Google Scholar
• MA W, QUIRION R: Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain (2002) 99:175-184.
   PubMed Web of Science ®Google Scholar
• ERIKSSON NP, PERSSON JK, SVENSSON M, ARVIDSSON J, MOLANDER C, ALDSKOGIUS H: A quantitative analysis of the microglial cell reaction in central primary sensory projection territories following peripheral nerve injury in the adult rat. Exp. Brain Res. (1993) 96:19-27.
   PubMed Web of Science ®Google Scholar
• MILLIGAN ED, TWINING C, CHACUR M et al.: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J. Neurosci. (2003) 23:1026-1040.
   PubMed Web of Science ®Google Scholar
• LEDEBOER A, SLOANE EM, MILLIGAN ED et al.: Minocycline attenuates mechanical allodynia and proinflammatory cytokine expression in rat models of pain facilitation. Pain (2005) 115:71-83.
   PubMed Web of Science ®Google Scholar
• HASHIZUME H, DELEO JA, COLBURN RW, WEINSTEIN JN: Spinal glial activation and cytokine expression after lumbar root injury in the rat. Spine (2000) 25:1206-1217.
   PubMed Web of Science ®Google Scholar
• VERGE GM, MILLIGAN ED, MAIER SF, WATKINS LR, NAEVE GS, FOSTER AC: Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) distribution in spinal cord and dorsal root ganglia under basal and neuropathic pain conditions. Eur. J. Neurosci. (2004) 20:1150-1160.
   PubMed Web of Science ®Google Scholar
• LINDIA JA, MCGOWAN E, JOCHNOWITZ N, ABBADIE C: Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain. J. Pain (2005) 6:434-438.
   Google Scholar
• MILLIGAN ED, ZAPATA V, CHACUR M et al.: Evidence that exogenous and endogenous fractalkine can induce spinal nociceptive facilitation in rats. Eur. J. Neurosci. (2004) 20:2294-2302.
   PubMed Web of Science ®Google Scholar
• INOUE K: ATP receptors of microglia involved in pain. Novartis Found Symp. (2006) 276:263-272.
   PubMedGoogle Scholar
• KIM SY, BAE JC, KIM JY et al.: Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport (2002) 13:2483-2486.
   PubMed Web of Science ®Google Scholar
• OBATA K, YAMANAKA H, DAI Y et al.: Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur. J. Neurosci. (2004) 20:2881-2895.
   PubMed Web of Science ®Google Scholar
• CIRUELA A, DIXON AK, BRAMWELL S, GONZALEZ MI, PINNOCK RD, LEE K: Identification of MEK1 as a novel target for the treatment of neuropathic pain. Br. J. Pharmacol. (2003) 138:751-756.
   PubMed Web of Science ®Google Scholar
• OBATA K, YAMANAKA H, KOBAYASHI K et al.: Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J. Neurosci. (2004) 24:10211-10222.
   PubMed Web of Science ®Google Scholar
• APFEL SC: Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? Int. Rev. Neurobiol. (2002) 50:393-413.
   PubMed Web of Science ®Google Scholar
• HALVORSON KG, KUBOTA K, SEVCIK MA et al.: A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. (2005) 65:9426-9435.
   PubMed Web of Science ®Google Scholar
• HA SO, KIM JK, HONG HS, KIM DS, CHO HJ: Expression of brain-derived neurotrophic factor in rat dorsal root ganglia, spinal cord and gracile nuclei in experimental models of neuropathic pain. Neuroscience (2001) 107:301-309.
   PubMed Web of Science ®Google Scholar
• MILETIC G, MILETIC V: Increases in the concentration of brain derived neurotrophic factor in the lumbar spinal dorsal horn are associated with pain behavior following chronic constriction injury in rats. Neurosci. Lett. (2002) 319:137-140.
   PubMed Web of Science ®Google Scholar
• FUKUOKA T, KONDO E, DAI Y, HASHIMOTO N, NOGUCHI K: Brain-derived neurotrophic factor increases in the uninjured dorsal root ganglion neurons in selective spinal nerve ligation model. J. Neurosci. (2001) 21:4891-4900.
   PubMed Web of Science ®Google Scholar
• WHITE DM: Neurotrophin-3 antisense oligonucleotide attenuates nerve injury-induced Aβ-fibre sprouting. Brain Res. (2000) 885:79-86.
   PubMed Web of Science ®Google Scholar
• DONG ZQ, WANG YQ, MA F, XIE H, WU GC: Down-regulation of GFRα-1 expression by antisense oligodeoxynucleotide aggravates thermal hyperalgesia in a rat model of neuropathic pain. Neuropharmacology (2006) 50:393-403.
   PubMed Web of Science ®Google Scholar
• NEGUS SS, VANDERAH TW, BRANDT MR, BILSKY EJ, BECERRA L, BORSOOK D: Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J. Pharmacol. Exp. Ther. (2006) 319:507-514.
   PubMed Web of Science ®Google Scholar
• MAO J, PRICE DD, HAYES RL, LU J, MAYER DJ: Differential roles of NMDA and non-NMDA receptor activation in induction and maintenance of thermal hyperalgesia in rats with painful peripheral mononeuropathy. Brain Res. (1992) 598(1-2):271-278.
   PubMed Web of Science ®Google Scholar
• SANG CN, BOOHER S, GILRON I, PARADA S, MAX MB: Dextromethorphan and memantine in painful diabetic neuropathy and postherpetic neuralgia: efficacy and dose-response trials. Anesthesiology (2002) 96(5):1053-1061.
   PubMed Web of Science ®Google Scholar
• BIAN D, NICHOLS ML, OSSIPOV MH, LAI J, PORRECA F: Characterization of the antiallodynic efficacy of morphine in a model of neuropathic pain in rats. Neuroreport (1995) 6(15):1981-1984.
   PubMed Web of Science ®Google Scholar
• EISENBERG E, MCNICOL ED, CARR DB: Efficacy and safety of opioid agonists in the treatment of neuropathic pain of nonmalignant origin: systematic review and meta-analysis of randomized controlled trials. JAMA (2005) 293(24):3043-3052.
   PubMed Web of Science ®Google Scholar
• MELLICK LB, MELLICK GA: Successful treatment of reflex sympathetic dystrophy with gabapentin. Am. J. Emerg. Med. (1995) 13:96.
   PubMed Web of Science ®Google Scholar
• SEGAL AZ, RORDORF G: Gabapentin as a novel treatment for postherpetic neuralgia. Neurology (1996) 46:1175-1176.
   PubMed Web of Science ®Google Scholar
• ROSNER H, RUBIN L, KESTENBAUM A: Gabapentin adjunctive therapy in neuropathic pain states. Clin. J. Pain (1996) 12:56-58.
   PubMed Web of Science ®Google Scholar
• XIAO WH, BENNETT GJ: Gabapentin has an antinociceptive effect mediated via a spinal site action in a rat model of painful peripheral neuropathy. Analgesia (1996) 2:267-273.
   Google Scholar
• HWANG JH, YAKSH TL: Effect of subarachnoid gabapentin on tactile-evoked allodynia in a surgically induced neuropathic pain model in the rat. Regional Anesthesia (1997) 22:249-256.
   Google Scholar
• BACKONJA M, BEYDOUN A, EDWARDS KR et al.: Gabapentin for the symptomatic treatment of painful neuropathy in patients with diabetes mellitus: a randomized controlled trial. JAMA (1998) 280:1831-1836.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM M, HARDEN N, STACEY B, BERNSTEIN P, MAGNUS-MILLER L: Gabapentin for the treatment of postherpetic neuralgia: a randomized controlled trial. JAMA (1998) 280:1837-1842.
   PubMed Web of Science ®Google Scholar
• GILRON I, FLATTERS SJ: Gabapentin and pregabalin for the treatment of neuropathic pain: a review of laboratory and clinical evidence. Pain Res Manag. (2006) 11(Suppl. A):16A-29A.
   Google Scholar
• LYNCH ME, CLARK AJ, SAWYNOK J, SULLIVAN MJ: Topical amitriptyline 2% and ketamine 1% in neuropathic pain syndromes: a randomized double blind placebo controlled trial. Anesthesiology (2005) 103:140-146.
   PubMed Web of Science ®Google Scholar
• SIMPSON S, BROWN S, CHANG S, JERMANO J; C107 STUDY GROUP: Controlled study of high-concentration capsaicin patch for painful HIV-associated distal sensory polyneuropathy. Abstracts of the 13th Conference on Retroviruses and Opportunistic Infections (2006) Abstract 79.
   Google Scholar
• DEECHER DC, BEYER CE, JOHNSTON G et al.: Desvenlafaxine succinate: a new serotonin and norepinephrine reuptake inhibitor. J. Pharmacol. Exp. Ther. (2006) 318(2):657-665.
   PubMed Web of Science ®Google Scholar
• EISENBERG E, LURIE Y, BRAKER C, DAOUD D, ISHAY A: Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Neurology (2001) 57(3):505-509.
   PubMed Web of Science ®Google Scholar
• SAFIRSTEIN B, TUCHMAN M, DOGRA S et al.: Efficacy of lamotrigine in painful diabetic neuropathy: results from two large double-blind trials. J. Pain (2005) 6(Suppl. 3):S34.
   Google Scholar
• GRAINGER J, HAMMER A, BLUM D, SILVER M, QUESSY S: Double-blind, placebo-controlled trial of add-on lamotrigine in patients with neuropathic pain and inadequate relief with gabapentin, TCAs or non-narcotic analgesics. J. Pain (2006) 7(Suppl. 2):S34.
   Google Scholar
• HARATI Y, GOOCH C, SWENSON M et al.: Double-blind randomized trial of tramadol for the treatment of the pain of diabetic neuropathy. Neurology (1998) 50(6):1842-1846.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, ANDERSEN G, MADSEN C, SMITH T, BROSEN K, JENSEN TS: Tramadol relieves pain and allodynia in polyneuropathy: a randomised, double-blind, controlled trial. Pain (1999) 83:85-90.
   PubMed Web of Science ®Google Scholar
• BOUREAU F, LEGALLICIER P, KABIR-AHMADI M: Tramadol in post-herpetic neuralgia: a randomized, double-blind, placebo-controlled trial. Pain (2003) 104(1-2):323-331.
   PubMed Web of Science ®Google Scholar
• COLLINS SD, CHESSELL IP: Emerging therapies for neuropathic pain. Expert Opin. Emerg. Drugs (2005) 10(1):95-108.
   Google Scholar
• MATA M, GLORIOSO JC, FINK DJ: Gene therapy: novel treatments for polyneuropathy and chronic pain. Curr. Neurol. Neurosci. Rep. (2004) 4(1):1-2.
   Google Scholar
• OXMAN MN, LEVIN MJ, JOHNSON GR et al.: A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N. Engl. J. Med. (2005) 352(22):2271-2284.
   PubMed Web of Science ®Google Scholar
• DAVIES PS, GALER BS: Review of lidocaine patch 5% studies in the treatment of postherpetic neuralgia. Drugs (2004) 64(9):937-947.
   PubMed Web of Science ®Google Scholar
• GILRON I, MAX MB: Combination pharmacotherapy for neuropathic pain: current evidence and future directions. Expert Rev. Neurother. (2005) 5(6):823-830.
   Google Scholar
• GILRON I, BAILEY JM, TU D, HOLDEN RR, WEAVER DF, HOULDEN RL: Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. (2005) 352(13):1324-1334.
   PubMed Web of Science ®Google Scholar
• MAX MB: Is mechanism-based pain treatment attainable? Clinical trial issues. J. Pain (2000) 1(3 Suppl.):2-9.
   Google Scholar
• MAX MB, LYNCH SA, MUIR J, SHOAF SE, SMOLLER B, DUBNER R: Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. N. Engl. J. Med. (1992) 326:1250-1256.
   PubMed Web of Science ®Google Scholar
• ROWBOTHAM MC, REISNER LA, DAVIES PS, FIELDS HL: Treatment response in antidepressant-naive postherpetic neuralgia patients: double-blind, randomized trial. J. Pain (2005) 6:741-746.
   Google Scholar
• WATSON CP, VERNICH L, CHIPMAN M, REED K: Nortriptyline versus amitriptyline in postherpetic neuralgia: a randomized trial. Neurology (1998) 51:1166-1171.
   PubMed Web of Science ®Google Scholar
• RAJA SN, HAYTHORNTHWAITE JA, PAPPAGALLO M et al.: Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology (2002) 59:1015-1021.
   PubMed Web of Science ®Google Scholar
• MORELLO CM, LECKBAND SG, STONER CP, MOORHOUSE DF, SAHAGIAN GA: Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain. Arch. Intern. Med. (1999) 159:1931-1937.
   PubMed Web of Science ®Google Scholar
• SINDRUP SH, BACH FW, MADSEN C, GRAM LF, JENSEN TS: Venlafaxine versus imipramine in painful polyneuropathy: a randomized, controlled trial. Neurology (2003) 60:1284-1289.
   PubMed Web of Science ®Google Scholar